A systematic review of datasets that can help elucidate relationships among gene expression, race, and immunohistochemistry-defined subtypes in breast cancer

References

• Sørlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, Børresen-Dale A-L. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 2006;7(1):127. doi:10.1186/1471-2164-7-127.
   PubMedGoogle Scholar
• Schnitt SJ. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc. 2010;23(Suppl 1):S60–4. doi:10.1038/modpathol.2010.33.
   PubMedGoogle Scholar
• Al-Ejeh F, Simpson PT, Sanus JM, Klein K, Kalimutho M, Shi W, Miranda M, Kutasovic J, Raghavendra A, Madore J, et al. Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer. Oncogenesis. 2014;3(4):e100. doi:10.1038/oncsis.2014.14.
   PubMedGoogle Scholar
• Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG, Cronin KA. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. JNCI: Journal of the National Cancer Institute. 2014;106(5). doi:10.1016/S1476-5586(04)80047-2.
   PubMedGoogle Scholar
• Davis M, Tripathi S, Hughley R, He Q, Bae S, Karanam B, Martini R, Newman L, Colomb W, Grizzle W, et al. 2018. AR negative triple negative or “quadruple negative” breast cancers in African American women have an enriched basal and immune signature. PLOS ONE. 13(6):e0196909. DOI:10.1371/journal.pone.0196909
   PubMed Web of Science ®Google Scholar
• Rubin I, Yarden Y. The basic biology of HER2. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO. 2001;12(Suppl 1):S3–8. doi:10.1093/annonc/12.suppl_1.S3.
   PubMed Web of Science ®Google Scholar
• Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M, Osborne CK. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol. 2005;56(Suppl S1):10–20. doi:10.1007/s00280-005-0108-2.
   PubMedGoogle Scholar
• Seton-Rogers S. Breast cancer: untangling the role of progesterone receptors. Nature reviews. Cancer. 2015;15(8):456.
   PubMed Web of Science ®Google Scholar
• Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26(45):6469–6487. doi:10.1038/sj.onc.1210477.
   PubMed Web of Science ®Google Scholar
• Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2009;27(8):1160–1167. doi:10.1200/JCO.2008.18.1370.
   PubMed Web of Science ®Google Scholar
• Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al.Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003 accessed 2020 Apr 6;100(14):8418–8423. doi:10.1073/pnas.0932692100.
   PubMed Web of Science ®Google Scholar
• Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, Shi B. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015;5(10):2929–2943.
   PubMed Web of Science ®Google Scholar
• Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2007;13(15):4429–4434. doi:10.1158/1078-0432.CCR-06-3045.
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–2767. doi:10.1172/JCI45014.
   PubMed Web of Science ®Google Scholar
• Siddharth S, Sharma D. 2018. Racial disparity and triple-negative breast cancer in African-American Women: a multifaceted affair between obesity, biology, and socioeconomic determinants. Cancers. 10(12):514. 10.3390/cancers10120514.
   PubMed Web of Science ®Google Scholar
• Amos KD, Adamo B, Anders CK. Triple-negative breast cancer: an update on neoadjuvant clinical trials. Int J Breast Cancer. 2012;2012:385978. doi:10.1155/2012/385978.
   PubMedGoogle Scholar
• Minckwitz G, von, von Minckwitz G, Untch M, Blohmer J-U, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, et al. 2012. Definition and Impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. Journal of Clinical Oncology. 30(15):1796–1804. DOI:10.1200/jco.2011.38.8595
   PubMedGoogle Scholar
• Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Fraser Symmans W, Gonzalez-Angulo AM, Hennessy B, Green M, et al. 2008. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. Journal of Clinical Oncology. 26(8):1275–1281. DOI:10.1200/jco.2007.14.4147
   PubMed Web of Science ®Google Scholar
• Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2007;13(8):2329–2334. doi:10.1158/1078-0432.CCR-06-1109.
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232(2):142–150. doi:10.1002/path.4280.
   PubMed Web of Science ®Google Scholar
• Penault-Llorca F, Viale G. Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO. 2012;23(Suppl 6):vi19–22. doi:10.1093/annonc/mds190.
   PubMedGoogle Scholar
• Henderson IC, Patek AJ. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat. 1998;52(1–3):261–288.
   PubMed Web of Science ®Google Scholar
• Haque R, Ahmed SA, Inzhakova G, Shi J, Avila C, Polikoff J, Bernstein L, Enger SM, Press MF. Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 2012;21(10):1848–1855. doi:10.1158/1055-9965.EPI-12-0474.
   PubMed Web of Science ®Google Scholar
• Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K, et al. Differences in breast carcinoma characteristics in newly diagnosed African--American and caucasian patients: a single-institution compilation compared with the national cancer institute’s surveillance, epidemiology, and end results database. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2007;110(4):876–884. doi:10.1002/cncr.22836.
   Google Scholar
• DeSantis C, Siegel R, Jemal A. Breast cancer facts & figures 2015-2016. Am Cancer Soc. 2015; 44.
   Google Scholar
• Meng L, Maskarinec G, Wilkens L. Ethnic differences and factors related to breast cancer survival in Hawaii. Int J Epidemiol. 1997;26(6):1151–1158. doi:10.1093/ije/26.6.1151.
   PubMed Web of Science ®Google Scholar
• Meng L, Maskarinec G, Lee J. Ethnicity and conditional breast cancer survival in Hawaii. J Clin Epidemiol. 1997;50(11):1289–1296. doi:10.1016/S0895-4356(97)00183-2.
   PubMed Web of Science ®Google Scholar
• Loi S, Piccart M, Sotiriou C. The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response. Crit Rev Oncol Hematol. 2007;61(3):187–194. doi:10.1016/j.critrevonc.2006.09.005.
   PubMed Web of Science ®Google Scholar
• Parada H, Sun X, Fleming JM, Williams-devane CR, Kirk EL, Olsson LT, Perou CM, Olshan AF, Troester MA. Race-associated biological differences among luminal A and basal-like breast cancers in the carolina breast cancer study. Breast Cancer Research. 2017;19(1). doi:10.1186/s13058-017-0914-6.
   PubMedGoogle Scholar
• Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, et al. NCBI GEO: archive for functional genomics data sets—update. Nucleic Acids Res. 2013;41(D1):D991–5. doi:10.1093/nar/gks1193.
   PubMed Web of Science ®Google Scholar
• Athar A, Füllgrabe A, George N, Iqbal H, Huerta L, Ali A, Snow C, Fonseca NA, Petryszak R, Papatheodorou I, et al. ArrayExpress update – from bulk to single-cell expression data. Nucleic Acids Res. 2019;47(D1):D711–D715. doi:10.1093/nar/gky964.
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6(1):1–6. doi:10.1016/S1476-5586(04)80047-2.
   PubMed Web of Science ®Google Scholar
• Brueffer C, Vallon-Christersson J, Grabau D, Ehinger A, Häkkinen J, Hegardt C, Malina J, Chen Y, Bendahl P-O, Manjer J, et al. Clinical Value of RNA sequencing–based classifiers for prediction of the five conventional breast cancer biomarkers: a report from the population-based multicenter sweden cancerome analysis network—breast initiative. JCO Precision Oncology. 2018;(2):1–18. doi:10.1200/po.17.00135.
   Google Scholar
• Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SAW, Savage MI, Osborne CK, Hilsenbeck SG, Chang JC, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2015;21(7):1688–1698. doi:10.1158/1078-0432.CCR-14-0432.
   PubMed Web of Science ®Google Scholar
• Den Hollander P, Rawls K, Tsimelzon A, Shepherd J, Mazumdar A, Hill J, Fuqua SAW, Chang JC, Osborne CK, Hilsenbeck SG, et al. Phosphatase PTP4A3 promotes triple-negative breast cancer growth and predicts poor patient survival. Cancer Res. 2016;76(7):1942–1953. doi:10.1158/0008-5472.CAN-14-0673.
   PubMed Web of Science ®Google Scholar
• Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham Y-L, Kalidas M, Elledge R, Mohsin S, Osborne CK, et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2005;23(6):1169–1177. doi:10.1200/JCO.2005.03.156.
   PubMed Web of Science ®Google Scholar
• Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo W-L, Lapuk A, Neve RM, Qian Z, Ryder T, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006;10(6):529–541. doi:10.1016/j.ccr.2006.10.009.
   PubMed Web of Science ®Google Scholar
• Creighton CJ, Sada YH, Zhang Y, Tsimelzon A, Wong H, Dave B, Landis MD, Bear HD, Rodriguez A, Chang JC. A gene transcription signature of obesity in breast cancer. Breast Cancer Res Treat. 2012;132(3):993–1000. doi:10.1007/s10549-011-1595-y.
   PubMed Web of Science ®Google Scholar
• Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346–352. doi:10.1038/nature10983.
   PubMed Web of Science ®Google Scholar
• Huang -C-C, Tu S-H, Lien -H-H, Jeng J-Y, Huang C-S, Huang C-J, Lai L-C, Chuang EY. Concurrent gene signatures for han chinese breast cancers. PloS One. 2013;8(10):e76421. doi:10.1371/journal.pone.0076421.
   PubMed Web of Science ®Google Scholar
• Julka PK, Chacko RT, Nag S, Parshad R, Nair A, Oh DS, Hu Z, Koppiker CB, Nair S, Dawar R, et al. A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling. Br J Cancer. 2008;98(8):1327–1335. doi:10.1038/sj.bjc.6604322.
   PubMed Web of Science ®Google Scholar
• Lin Y, Lin S, Watson M, Trinkaus KM, Kuo S, Naughton MJ, Weilbaecher K, Fleming TP, Aft RL. A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2010;123(3):691–699. doi:10.1007/s10549-009-0664-y.
   PubMed Web of Science ®Google Scholar
• Lindner R, Sullivan C, Offor O, Lezon-Geyda K, Halligan K, Fischbach N, Shah M, Bossuyt V, Schulz V, Tuck DP, et al. 2013. Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapy. PloS One. 8(11):e71915. DOI:10.1371/journal.pone.0071915
   PubMed Web of Science ®Google Scholar
• Loi S, Sotiriou C, Haibe-Kains B, Lallemand F, Conus NM, Piccart MJ, Speed TP, McArthur GA. Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer. BMC Med Genomics. 2009;2(1):37. doi:10.1186/1755-8794-2-37.
   PubMedGoogle Scholar
• Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, et al. Definition of clinically distinct molecular subtypes in estrogen receptor–positive breast carcinomas through genomic grade. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2007;25(10):1239–1246. doi:10.1200/JCO.2006.07.1522.
   PubMed Web of Science ®Google Scholar
• Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF, et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics. 2008;9(1):239. doi:10.1186/1471-2164-9-239.
   PubMedGoogle Scholar
• Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Fraser Symmans W, Bardelli A, et al.PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A. 2010 accessed 2020 Mar 6;107(22):10208–10213. doi:10.1073/pnas.0907011107.
   PubMed Web of Science ®Google Scholar
• Lu X, Lu X, Wang ZC, Iglehart JD, Zhang X, Richardson AL. Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat. 2008;108(2):191–201. doi:10.1007/s10549-007-9596-6.
   PubMed Web of Science ®Google Scholar
• Miyake T, Nakayama T, Naoi Y, Yamamoto N, Otani Y, Kim SJ, Shimazu K, Shimomura A, Maruyama N, Tamaki Y, et al. 2012. GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer. Cancer Sci. 103(5):913–920. DOI:10.1111/j.1349-7006.2012.02231.x
   PubMed Web of Science ®Google Scholar
• Pawitan Y, Bjöhle J, Amler L, Borg A-L, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Research: BCR. 2005;7(6):R953–64. doi:10.1186/bcr1325.
   PubMed Web of Science ®Google Scholar
• Hall P, Ploner A, Bjöhle J, Huang F, Lin C-Y, Liu ET, Miller LD, Nordgren H, Pawitan Y, Shaw P, et al. Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. BMC Med. 2006;4(1):16. doi:10.1186/1741-7015-4-16.
   PubMedGoogle Scholar
• Prat A, Bianchini G, Thomas M, Belousov A, Cheang MCU, Koehler A, Gomez P, Semiglazov V, Eiermann W, Tjulandin S, et al. 2014. Research-Based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. Clinical Cancer Research. 20(2):511–521. DOI:10.1158/1078-0432.ccr-13-0239
   PubMed Web of Science ®Google Scholar
• Rahman M, Jackson LK, Johnson WE, Li DY, Bild AH, Piccolo SR. Alternative preprocessing of RNA-Sequencing data in the cancer genome atlas leads to improved analysis results. Bioinformatics. 2015;31(22):3666–3672. doi:10.1093/bioinformatics/btv377.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. doi:10.1038/nature11412.
   PubMed Web of Science ®Google Scholar
• Popovici V, Chen W, Gallas BG, Hatzis C, Shi W, Samuelson FW, Nikolsky Y, Tsyganova M, Ishkin A, Nikolskaya T, et al. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Research: BCR. 2010;12(1):R5. doi:10.1186/bcr2468.
   PubMed Web of Science ®Google Scholar
• Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, Su Z, Chu T-M, Goodsaid FM, Pusztai L, et al. 2010. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol. 28(8):827–838.
   PubMed Web of Science ®Google Scholar
• Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Barajas-Figueroa LJ, Souchon E, Coutant C, et al. 2010. Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clinical Cancer Research. 16(21):5351–5361. DOI:10.1158/1078-0432.ccr-10-1265
   PubMed Web of Science ®Google Scholar
• Ulirsch J, Fan C, Knafl G, Wu MJ, Coleman B, Perou CM, Swift-Scanlan T. Vimentin DNA methylation predicts survival in breast cancer. Breast Cancer Res Treat. 2013;137(2):383–396. doi:10.1007/s10549-012-2353-5.
   PubMed Web of Science ®Google Scholar
• Wang J, Scholtens D, Holko M, Ivancic D, Lee O, Hu H, Chatterton RT Jr, Sullivan ME, Hansen N, Bethke K, et al. Lipid metabolism genes in contralateral unaffected breast and estrogen receptor status of breast cancer. Cancer Prevention Research. 2013;6(4):321–330. doi:10.1158/1940-6207.CAPR-12-0304.
   PubMed Web of Science ®Google Scholar
• Guarneri V, Broglio K, Kau S-W, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2006;24(7):1037–1044. doi:10.1200/JCO.2005.02.6914.
   PubMed Web of Science ®Google Scholar
• Ali S, Mondal N, Choudhry H, Rasool M, Pushparaj PN, Khan MA, Mahfooz M, Sami GA, Jarullah J, Ali A, et al. Current management strategies in breast cancer by targeting key altered molecular players. Front Oncol. 2016;6:45. doi:10.3389/fonc.2016.00045.
   PubMed Web of Science ®Google Scholar
• Jacquet E, Lardy-Cléaud A, Pistilli B, Franck S, Cottu P, Delaloge S, Debled M, Vanlemmens L, Leheurteur M, Guizard AV, et al. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients. Eur J Cancer. 2018;95:93–101. doi:10.1016/j.ejca.2018.03.013.
   PubMed Web of Science ®Google Scholar
• Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011;5(1):5–23. doi:10.1016/j.molonc.2010.11.003.
   PubMed Web of Science ®Google Scholar
• Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Research: BCR. 2007;9(1):R6. doi:10.1186/bcr1639.
   PubMed Web of Science ®Google Scholar
• Yersal O, Barutca S. Biological subtypes of breast cancer: prognostic and therapeutic implications. World J Clin Oncol. 2014;5(3):412–424. doi:10.5306/wjco.v5.i3.412.
   PubMedGoogle Scholar
• Prat A, Bianchini G, Thomas M, Belousov A, Cheang MCU, Koehler A, Gómez P, Semiglazov V, Eiermann W, Tjulandin S, et al. Research-Based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH Study. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2014;20(2):511–521. doi:10.1158/1078-0432.CCR-13-0239.
   PubMed Web of Science ®Google Scholar
• Yedjou CG, Sims JN, Miele L, Noubissi F, Lowe L, Fonseca DD, Alo RA, Payton M, Tchounwou PB. Health and racial disparity in breast cancer. Advances in Experimental Medicine and Biology. 2019;1152:31–49.
   PubMed Web of Science ®Google Scholar
• Foy KC, Fisher JL, Lustberg MB, Gray DM, DeGraffinreid CR, Paskett ED, Foy KC, Fisher JL, Lustberg MB, Gray DM, et al. Disparities in breast cancer tumor characteristics, treatment, time to treatment, and survival probability among African American and white women. NPJ Breast Cancer. 2018;4(1):7. doi:10.1038/s41523-018-0059-5.
   PubMedGoogle Scholar
• Hill HE, Schiemann WP, Varadan V. Understanding breast cancer disparities—a multi-scale challenge. Annals of Translational Medicine. 2020;8(14):906. doi:10.21037/atm.2020.04.37.
   PubMed Web of Science ®Google Scholar
• DeSantis C, Ma J, Bryan L, Jemal A. 2014. Breast cancer statistics, 2013. CA Cancer J Clin. 64(1):52–62. 10.3322/caac.21203.
   PubMed Web of Science ®Google Scholar
• Power EJ, Chin ML, Haq MM. Breast cancer incidence and risk reduction in the hispanic population. Cureus. 2018;10(2):e2235.
   PubMed Web of Science ®Google Scholar
• Copson E, Maishman T, Gerty S, Eccles B, Stanton L, Cutress RI, Altman DG, Durcan L, Simmonds P, Jones L, et al. Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study. Br J Cancer. 2014;110(1):230–241. doi:10.1038/bjc.2013.650.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A. et al., SEER cancer statistics review, 1975-2014. Bethesda (MD): National Cancer Institute. 2017. 2018.
   Google Scholar
• Brinton LA, Figueroa JD, Awuah B, Yarney J, Wiafe S, Wood SN, Ansong D, Nyarko K, Wiafe-Addai B, Clegg-Lamptey JN. Breast cancer in Sub-Saharan Africa: opportunities for prevention. Breast Cancer Res Treat. 2014;144(3):467–478. doi:10.1007/s10549-014-2868-z.
   PubMed Web of Science ®Google Scholar
• Smith-Bindman R, Miglioretti DL, Lurie N, Abraham L, Barbash RB, Strzelczyk J, Dignan M, Barlow WE, Beasley CM, Kerlikowske K. Does utilization of screening mammography explain racial and ethnic differences in breast cancer? Ann Intern Med. 2006;144(8):541–553. doi:10.7326/0003-4819-144-8-200604180-00004.
   PubMed Web of Science ®Google Scholar
• Gomez SL, Clarke CA, Shema SJ, Chang ET, Keegan THM, Glaser SL. Disparities in breast cancer survival among Asian women by ethnicity and immigrant status: a population-based study. Am J Public Health. 2010;100(5):861–869. doi:10.2105/AJPH.2009.176651.
   PubMed Web of Science ®Google Scholar
• Dietze EC, Sistrunk C, Miranda-Carboni G, O’Regan R, Seewaldt VL. Triple-negative breast cancer in African-American women: disparities versus biology. Nature reviews. Cancer. 2015;15(4):248–254.
   PubMed Web of Science ®Google Scholar
• Rhodes A, Jasani B, Barnes DM, Bobrow LG, Miller KD. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol. 2000;53(2):125–130. doi:10.1136/jcp.53.2.125.
   PubMed Web of Science ®Google Scholar
• Chebil G, Bendahl P-O, Ferno M. Estrogen and progesterone receptor assay in paraffin-embedded breast cancer. Acta oncologica. 2003;42(1):43–47. doi:10.1080/02841860300672.
   PubMed Web of Science ®Google Scholar
• Sturtz LA, Melley J, Mamula K, Shriver CD, Ellsworth RE. Outcome disparities in African American women with triple negative breast cancer: a comparison of epidemiological and molecular factors between African American and Caucasian women with triple negative breast cancer. BMC Cancer. 2014;14(1). doi:10.1186/1471-2407-14-62.
   PubMedGoogle Scholar
• Huo D, Hu H, Rhie SK, Gamazon ER, Cherniack AD, Liu J, Yoshimatsu TF, Pitt JJ, Hoadley KA, Troester M, et al. 2017. Comparison of breast cancer molecular features and survival by African and European Ancestry in the cancer genome atlas. JAMA Oncology. 3(12):1654. DOI:10.1001/jamaoncol.2017.0595
   PubMed Web of Science ®Google Scholar
• Chavez-MacGregor M, Liu S, De Melo-Gagliato D, Chen H, Do KA, Pusztai L, Symmans WF, Nair L, Hortobagyi GN, Mills GB, et al. Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 2014;23(2):316–323. doi:10.1158/1055-9965.EPI-13-0929.
   PubMed Web of Science ®Google Scholar
• Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Mechanisms of Tamoxifen Resistance: increased Estrogen Receptor-HER2/neu Cross-Talk in ER/HER2-positive breast cancer. JNCI Journal of the National Cancer Institute. 2004 accessed 2020 Jun 19;96(12):926–935. doi:10.1093/jnci/djh166.
   PubMedGoogle Scholar
• Ching T, Huang S, Garmire LX. Power analysis and sample size estimation for RNA-Seq differential expression. RNA. 2014;20(11):1684–1696. doi:10.1261/rna.046011.114.
   PubMed Web of Science ®Google Scholar
• Toro-Domínguez D, Villatoro-García JA, Martorell-Marugán J, Román-Montoya Y, Alarcón-Riquelme ME, Carmona-Sáez P. A survey of gene expression meta-analysis: methods and applications. Brief Bioinform. 2020 Feb 25. 10.1093/bib/bbaa019.
   Google Scholar
• Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A’Hern R, Salter J, Detre S, Hills M, Walsh G, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. JNCI: Journal of the National Cancer Institute. 2007;99(2):167–170. doi:10.1093/jnci/djk020.
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn H-J, Albain KS, André F, Bergh J. Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer 2013. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO. 2013;24(9):2206–2223. doi:10.1093/annonc/mdt303.
   PubMed Web of Science ®Google Scholar
• Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. The Lancet. 2003;362(9381):362–369. doi:10.1016/S0140-6736(03)14023-8.
   PubMed Web of Science ®Google Scholar
• Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, et al. 2004. Gene expression profiles predict complete pathologic response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide chemotherapy in breast cancer. Journal of Clinical Oncology. 22(12):2284–2293. DOI:10.1200/jco.2004.05.166
   PubMed Web of Science ®Google Scholar
• Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi:10.1186/s13059-014-0550-8.
   PubMed Web of Science ®Google Scholar
• Liao Y, Smyth GK, Shi W. The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. Nucleic Acids Res. 2019;47(8):e47. doi:10.1093/nar/gkz114.
   PubMed Web of Science ®Google Scholar
• Wesolowski R, Ramaswamy B. Gene expression profiling: changing face of breast cancer classification and management. Gene Expr. 2011;15(3):105–115. doi:10.3727/105221611X13176664479241.
   PubMed Web of Science ®Google Scholar
• Yang YH, Xiao Y, Segal MR. Identifying differentially expressed genes from microarray experiments via statistic synthesis. Bioinformatics. 2005;21(7):1084–1093. doi:10.1093/bioinformatics/bti108.
   PubMed Web of Science ®Google Scholar
• Gaujoux R, Seoighe C. A flexible R package for nonnegative matrix factorization. BMC Bioinform. 2010;11(1):367. doi:10.1186/1471-2105-11-367.
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences. 98(19):10869–10874. DOI:10.1073/pnas.191367098
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Neo S-Y, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A. 2003;100(18):10393–10398. doi:10.1073/pnas.1732912100.
   PubMed Web of Science ®Google Scholar
• Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. doi:10.1038/35021093.
   PubMed Web of Science ®Google Scholar
• Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, Díez M, Viladot M, Arance A, Muñoz M. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24(Suppl 2):S26–35. doi:10.1016/j.breast.2015.07.008.
   PubMed Web of Science ®Google Scholar
• Bertucci F, Finetti P, Cervera N, Esterni B. How basal are triple negative breast cancers? J Cancer. 2008. https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.23518
   Web of Science ®Google Scholar
• Sørlie T, Borgan E, Myhre S, Vollan HK, Russnes H, Zhao X, Nilsen G, Lingjaerde OC, Børresen-Dale A-L, Rødland E. The importance of gene-centring microarray data. Lancet Oncol. 2010;11(8):719–720. doi:10.1016/S1470-2045(10)70174-1. author reply 720–1.
   PubMed Web of Science ®Google Scholar
• Raj-Kumar P-K, Liu J, Hooke JA, Kovatich AJ, Kvecher L, Shriver CD, Hu H. PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B. Sci Rep. 2019;9(1):7956. doi:10.1038/s41598-019-44339-4.
   PubMedGoogle Scholar
• Roelands J, Decock J, Boughorbel S, Rinchai D, Maccalli C, Ceccarelli M, Black M, Print C, Chou J, Presnell S, et al. 2017. A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification. F1000Research. 6:296. 10.12688/f1000research.10960.1.
   PubMedGoogle Scholar
• Karn T, Pusztai L, Holtrich U, Iwamoto T, Shiang CY, Schmidt M, Müller V, Solbach C, Gaetje R, Hanker L, et al. Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures. PloS One. 2011;6(12):e28403. doi:10.1371/journal.pone.0028403.
   PubMed Web of Science ®Google Scholar
• Gong M, Ye S, Lv W, He K, Li W. Comprehensive integrated analysis of gene expression datasets identifies key anti cancer targets in different stages of breast cancer. Exp Ther Med. 2018. accessed 2020 Apr 8. 16(2):802–810.
   PubMed Web of Science ®Google Scholar
• Leek JT, Scharpf RB, Bravo HC, Simcha D, Langmead B, Johnson WE, Geman D, Baggerly K, Irizarry RA. Tackling the widespread and critical impact of batch effects in high-throughput data. Nature Reviews Genetics. 2010;11(10):733–739. doi:10.1038/nrg2825.
   PubMed Web of Science ®Google Scholar
• Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012;28(6):882–883. doi:10.1093/bioinformatics/bts034.
   PubMed Web of Science ®Google Scholar
• Waldron L, Riester M. Meta-analysis in gene expression studies. Methods in Molecular Biology. 2016;161–176. doi:10.1007/978-1-4939-3578-9_8.
   PubMedGoogle Scholar
• Patil P, Parmigiani G. Training replicable predictors in multiple studies. Proc Natl Acad Sci U S A. 2018;115(11):2578–2583. doi:10.1073/pnas.1708283115.
   PubMed Web of Science ®Google Scholar
• Gonçalves RS, Musen MA. The variable quality of metadata about biological samples used in biomedical experiments. Scientific Data. 2019;6(1):190021. doi:10.1038/sdata.2019.21.
   PubMedGoogle Scholar
• Gendoo DMA, Zon M, Sandhu V, Manem VSK, Ratanasirigulchai N, Chen GM, Waldron L, Haibe-Kains B. MetaGxData: clinically annotated breast, ovarian and pancreatic cancer datasets and their use in generating a multi-cancer gene signature. Sci Rep. 2019;9(1):8770. doi:10.1038/s41598-019-45165-4.
   PubMedGoogle Scholar
• Gibson G. The environmental contribution to gene expression profiles. Nature Reviews Genetics. 2008;9(8):575–581. doi:10.1038/nrg2383.
   PubMed Web of Science ®Google Scholar
• Wilkinson MD, Dumontier M, Aalbersberg IJJ, Appleton G, Axton M, Baak A, Blomberg N, Boiten J-W, da Silva Santos LB, Bourne PE, et al. The FAIR guiding principles for scientific data management and stewardship. Scientific Data. 2016;3(1):160018. doi:10.1038/sdata.2016.18.
   PubMed Web of Science ®Google Scholar
• Hippen AA, Greene CS. Expanding and remixing the metadata landscape. Trends Cancer Res. 2021;7(4):276–278. doi:10.1016/j.trecan.2020.10.011.
   Google Scholar